These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 37376634)
1. Novel Mode of nanoLuciferase Packaging in SARS-CoV-2 Virions and VLPs Provides Versatile Reporters for Virus Production. Gullberg RC; Frydman J Viruses; 2023 Jun; 15(6):. PubMed ID: 37376634 [TBL] [Abstract][Full Text] [Related]
2. Assembly and Entry of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2): Evaluation Using Virus-Like Particles. Kumar B; Hawkins GM; Kicmal T; Qing E; Timm E; Gallagher T Cells; 2021 Apr; 10(4):. PubMed ID: 33918600 [TBL] [Abstract][Full Text] [Related]
3. Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus. Chiem K; Park JG; Morales Vasquez D; Plemper RK; Torrelles JB; Kobie JJ; Walter MR; Ye C; Martinez-Sobrido L Microbiol Spectr; 2022 Oct; 10(5):e0237922. PubMed ID: 35980204 [TBL] [Abstract][Full Text] [Related]
4. Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2. Morales Vasquez D; Chiem K; Silvas J; Park JG; Ye C; Martínez-Sobrido L J Vis Exp; 2021 Nov; (177):. PubMed ID: 34806704 [TBL] [Abstract][Full Text] [Related]
5. Properties of Coronavirus and SARS-CoV-2. Malik YA Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926 [TBL] [Abstract][Full Text] [Related]
6. Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. Hsieh PK; Chang SC; Huang CC; Lee TT; Hsiao CW; Kou YH; Chen IY; Chang CK; Huang TH; Chang MF J Virol; 2005 Nov; 79(22):13848-55. PubMed ID: 16254320 [TBL] [Abstract][Full Text] [Related]
7. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus. Garg H; Sedano M; Plata G; Punke EB; Joshi A J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019 [TBL] [Abstract][Full Text] [Related]
8. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Xie X; Muruato AE; Zhang X; Lokugamage KG; Fontes-Garfias CR; Zou J; Liu J; Ren P; Balakrishnan M; Cihlar T; Tseng CK; Makino S; Menachery VD; Bilello JP; Shi PY bioRxiv; 2020 Jun; ():. PubMed ID: 32607511 [TBL] [Abstract][Full Text] [Related]
9. Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2. Chang YS; Chu LW; Chen ZY; Wu JS; Su WC; Yang CJ; Ping YH; Lin CW Viruses; 2022 Dec; 14(12):. PubMed ID: 36560829 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Serologic Cross-Reactivity Between Dengue Virus and SARS-CoV-2 in Patients with Acute Febrile Illness - United States and Puerto Rico, April 2020-March 2021. Munoz-Jordan J; Cardona J; Beltrán M; Colón C; Schiffer J; Stewart-Clark E; Zellner B; Semenova V; Li Y; Jia LT; Maniatis P; Pawloski L; Adams L; Paz-Bailey G; Rivera-Amill V; Medina F MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):375-377. PubMed ID: 35271558 [TBL] [Abstract][Full Text] [Related]
11. A Versatile Nanoluciferase Reporter Reveals Structural Properties Associated with a Highly Efficient, N-Terminal Legionella pneumophila Type IV Secretion Translocation Signal. Kang YS; Kirby JE Microbiol Spectr; 2023 Feb; 11(2):e0233822. PubMed ID: 36815834 [TBL] [Abstract][Full Text] [Related]
12. Optimization of a DNA-launched SARS-CoV-2 replicon with RNA splicing inhibitor Isoginkgetin. Zhang H; Guo H J Med Virol; 2024 Mar; 96(3):e29547. PubMed ID: 38511574 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV envelope protein palmitoylation or nucleocapid association is not required for promoting virus-like particle production. Tseng YT; Wang SM; Huang KJ; Wang CT J Biomed Sci; 2014 Apr; 21(1):34. PubMed ID: 24766657 [TBL] [Abstract][Full Text] [Related]
14. RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System. Raheja H; Das S; Banerjee A; P D; C D; Mukhopadhyay D; Ramachandra SG; Das S Microbiol Spectr; 2022 Aug; 10(4):e0078122. PubMed ID: 35862952 [TBL] [Abstract][Full Text] [Related]
15. One-plasmid double-expression system for preparation of MS2 virus-like particles packaging SARS-CoV-2 RNA. Qi L; Zhang Z; Wang M; Ke Z; Mao H; Deng G; Wang J Front Cell Infect Microbiol; 2023; 13():1238543. PubMed ID: 38094745 [TBL] [Abstract][Full Text] [Related]
16. Optimized production and fluorescent labeling of SARS-CoV-2 virus-like particles. Gourdelier M; Swain J; Arone C; Mouttou A; Bracquemond D; Merida P; Saffarian S; Lyonnais S; Favard C; Muriaux D Sci Rep; 2022 Aug; 12(1):14651. PubMed ID: 36030323 [TBL] [Abstract][Full Text] [Related]
17. Preparation of the luciferase-labeled antibody for improving the detection sensitivity of viral antigen. Tang Y; Li Y; Zhang S; Li J; Hu Y; Yang W; Chen Y; Qin C; Jiang T; Kang X Virol J; 2022 Jul; 19(1):126. PubMed ID: 35902865 [TBL] [Abstract][Full Text] [Related]
18. Development and Characterization of a Highly Sensitive NanoLuciferase-Based Immunoprecipitation System for the Detection of Anti-Influenza Virus HA Antibodies. Honda T; Gomi S; Yamane D; Yasui F; Yamamoto T; Munakata T; Itoh Y; Ogasawara K; Sanada T; Yamaji K; Yasutomi Y; Tsukiyama-Kohara K; Kohara M mSphere; 2021 May; 6(3):. PubMed ID: 33980684 [TBL] [Abstract][Full Text] [Related]
19. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]